VYYRF
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $19,271 | -$165,113 |
| 2025 Q4 | -0.00 | $644 | -$369,550 |
| 2025 Q3 | -0.01 | $11,033 | -$1M |
| 2025 Q2 | -0.00 | $0 | -$260,689 |
| 2025 Q1 | -0.01 | $0 | -$1M |
| 2024 Q4 | -0.00 | $0 | $81,141 |
| 2024 Q3 | -0.00 | $0 | -$11,070 |
| 2024 Q2 | -0.00 | $0 | -$227,394 |